Zobrazeno 1 - 10
of 290
pro vyhledávání: '"Dipeptidyl peptidase 4 inhibitor"'
Autor:
Dana Shalmon, Efrat Bar-Ilan, Alon Peled, Shamir Geller, Jonathan Bar, Naama Schwartz, Eli Sprecher, Mor Pavlovsky
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A re
Externí odkaz:
https://doaj.org/article/684713bdbf404574b01afb83b8cedbfc
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 13, Iss , Pp 100429- (2024)
Background: Antihyperglycemic drug utilization studies are conducted frequently and describe the uptake of new drug therapies across may jurisdictions. An increasingly important, yet often absent, aspect of these studies is the impact of rurality on
Externí odkaz:
https://doaj.org/article/6f230647679048cfbeb6aa180251f269
Autor:
Jieun Yang, Se Hyun Kim, Eun Hee Jung, Sang‐A Kim, Koung Jin Suh, Ji Yun Lee, Ji‐Won Kim, Jin Won Kim, Jeong‐Ok Lee, Yu Jung Kim, Keun‐Wook Lee, Jee Hyun Kim, Soo‐Mee Bang, Jong Seok Lee
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 52-60 (2023)
Abstract Background Preclinical data have shown the immunomodulatory effects of metformin and dipeptidyl peptidase 4 (DPP4) inhibitors in patients with diabetes. However, its clinical impact remains unclear in lung cancer. Methods Between 2017 and 20
Externí odkaz:
https://doaj.org/article/89462ac6a64746f8a81e22adbc3245db
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Publikováno v:
Clinical and Molecular Hepatology, Vol 28, Iss 3, Pp 497-509 (2022)
Background/Aims We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods An exploration study (study I) was pe
Externí odkaz:
https://doaj.org/article/df6858c4f9f14c0781d449633c22ed0d
Autor:
Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Yuichi Ito, Sonoko Kitao, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, Hiroko Okura, Kazuhiko Matsuzawa, Shoichiro Izawa, Etsuko Ueta, Masahiko Kato, Takeshi Imamura, Shin-ichi Taniguchi, Kazuhiro Yamamoto
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 14, Iss 1, Pp 1-6 (2022)
Abstract Background Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established
Externí odkaz:
https://doaj.org/article/3bc35e08618a46a9b79bd2abf5fded01
Autor:
Shaimaa N. Amin, Hader I. Sakr, Walaa B. El Gazzar, Sherif A. Shaltout, Hazem S. Ghaith, Dalia A. Elberry
Publikováno v:
PeerJ, Vol 11, p e14724 (2023)
Acute kidney injury (AKI) is a prevalent medical condition accompanied by mutual affection of other organs, including the liver resulting in complicated multiorgan malfunction. Macrophages play a vital role during tissue injury and healing; they are
Externí odkaz:
https://doaj.org/article/7af95f1304cb4bad9345be4d9bafbeb0
Autor:
Keisuke Nozawa, Takahide Suzuki, Gen Kayanuma, Hiroki Yamamoto, Kazuki Nagayasu, Hisashi Shirakawa, Shuji Kaneko
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
Recent studies have suggested that dipeptidyl peptidase 4 (DPP4) inhibitors increase the risk of development of bullous pemphigoid (BP), which is the most common autoimmune blistering skin disease; however, the associated mechanisms remain unclear, a
Externí odkaz:
https://doaj.org/article/d11d0e1019914db8b8e80d4eec6d8d88
Autor:
Sachiko Hattori
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-7 (2021)
Abstract Background Early and effective intervention with a dipeptidyl peptidase 4 inhibitor (DPP4i) before the development of advanced atherosclerosis in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease (CVD) is r
Externí odkaz:
https://doaj.org/article/267e565dd71d4be1a46370ef1d56d6d7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.